Chemi-Verse™ SIK2 Kinase Assay Kit

Catalog #
82106
$775 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Chemi-Verse™ SIK2 Kinase Assay Kit is designed to measure SIK2 (salt inducible kinase 2) kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified recombinant SIK2 kinase, kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions.

Synonyms
Qin-induced kinase, Salt-inducible kinase 2 (SIK-2), Serine/threonine-protein kinase SNF1-like kinase 2, Serine/threonine-protein kinase SIK2, KIAA0781, QIK, SNF1LK2
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Materials Required But Not Supplied
  • ADP-Glo™ Kinase Assay (Promega #V6930)
  • DTT (Dithiothreitol), 1M, optional
  • Microplate reader capable of reading luminescence
  • Adjustable micropipettor and sterile tips
  • 30°C incubator
Format
Catalog # Name Amount Storage
  SIK2 2.5 µg -80°C
79334 5x Kinase Buffer 1 1.5 ml -20°C
79686 500 µM ATP 50 µl -20°C
  Amara Peptide (1 mg/ml) 500 µl -20°C
79696 White 96-well plate 1 Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube.

UniProt #
Q9H0K1
Background

SIK (salt-inducible kinases) are serine/threonine kinases of the AMPK (AMP-activated protein kinase) family. They are involved in gluconeogenesis and lipid metabolism inhibition. Dysfunction of SIK has been linked to cancer, due to its association with the TGFβ (transforming growth factor β)-Smad, AKT (protein kinase B), Hippo and NF-κB (nuclear factor kappa-light chain enhancer of activated B cells) pathways. The role of SIK proteins in cancer is complex, with some family members acting as oncogenes while others functioning as suppressors. SIK2 is widely expressed and is a potential oncogene in ovarian, prostate cancer, glioma and diffuse large B-cell lymphoma (DLBCL). It promotes cancer in multiple ways: inhibits cell apoptosis, promotes G1 to S cell phase, modulates glucose metabolism, inhibits autophagy and facilitates EMT (epithelial-mesenchymal transition). It accomplishes these roles by repressing AKT (protein kinase B) phosphorylation, activating PI3K (phosphoinositide 3 kinase) via p85α and linking to the PI3K/AKT/HIF1α pathway. The development of SIK inhibitors is the focus of intense research, but further studies are needed to identify isoform-specific inhibitors targeting SIK2 that can be used in cancer therapy. 

References

Sun Z., et al., 2020, Signal Transduction and Targeted Therapy 5:150.